Idoia Martín-Guerrero

Dr. Idoia Martín-Guerrero

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2011 in Blood
Verified
Journal Article
Closed access
PDF file
ISItziar Salaverria
Itziar Salaverria
CPClaudia Philipp
Claudia Philipp
IOIlske Oschlies
Ilske Oschlies
CKChristian W. Kohler
Christian W. Kohler
MKMarkus Kreuz
Markus Kreuz
TGthe Berlin-Frankfurt-Münster-NHL trial group
the Berlin-Frankfurt-Münster-NHL trial group
The prognosis of germinal center–derived B-cell (GCB) lymphomas, including follicular lymphoma and diffuse large-B-cell lymphoma (DLBCL), strongly depends on age. Children have a more favorable outcome than adults. It is not known whether this is because of differences in host characteristics, treatment protocols, or tumor biology, including the presence of chromosomal alterations. By screening for novel IGH translocation partners in pediatric and adult lymphomas, we identified chromosomal translocations juxtaposing the IRF4 oncogene next to one of the immunoglobulin (IG) loci as a novel recurrent aberration in mature B-cell lymphoma. FISH revealed 20 of 427 lymphomas to carry an IG/IRF4-fusion. Those were predominantly GCB-type DLBCL or follicular lymphoma grade 3, shared strong expression of IRF4/MUM1 and BCL6, and lacked PRDM1/BLIMP1 expression and t(14;18)/BCL2 breaks. BCL6 aberrations were common. The gene expression profile of IG/IRF4-positive lymphomas differed from other subtypes of DLBCL. A classifier for IG/IRF4 positivity containing 27 genes allowed accurate prediction. IG/IRF4 positivity was associated with young age and a favorable outcome. Our results suggest IRF4 translocations to be primary alterations in a molecularly defined subset of GCB-derived lymphomas. The probability for this subtype of lymphoma significantly decreases with age, suggesting that diversity in tumor biology might contribute to the age-dependent differences in prognosis of lymphoma.

20 February 2014 in Blood
Verified
Journal Article
Open access
PDF file
ISItziar Salaverria
Itziar Salaverria
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
RWRabea Wagener
Rabea Wagener
MKMarkus Kreuz
Markus Kreuz
CKChristian W. Kohler
Christian W. Kohler
RSReiner Siebert
Reiner Siebert
Key Points: A subset of lymphomas with gene expression and pathological characteristics of Burkitt lymphomas but absence of MYC translocation does exist. These lymphomas carry chr 11q proximal gains and telomeric losses, suggesting co-deregulation of oncogenes and tumor suppressor genes.

23 January 2020 in Blood
Verified
Journal Article
Open access
PDF file
JRJoan Enric Ramis-Zaldivar
Joan Enric Ramis-Zaldivar
BGBlanca Gonzalez-Farré
Blanca Gonzalez-Farré
OPOlga Balagué Ponz
Olga Balagué Ponz
VCVerónica Celis
Verónica Celis
FNFerran Nadeu
Ferran Nadeu
ISItziar Salaverria
Itziar Salaverria
Pediatric large B-cell lymphomas (LBCLs) share morphological and phenotypic features with adult types but have better prognosis. The higher frequency of some subtypes such as LBCL with IRF4 rearrangement (LBCL-IRF4) in children suggests that some age-related biological differences may exist. To characterize the genetic and molecular heterogeneity of these tumors, we studied 31 diffuse LBCLs (DLBCLs), not otherwise specified (NOS); 20 LBCL-IRF4 cases; and 12 cases of high-grade B-cell lymphoma (HGBCL), NOS in patients ≤25 years using an integrated approach, including targeted gene sequencing, copy-number arrays, and gene expression profiling. Each subgroup displayed different molecular profiles. LBCL-IRF4 had frequent mutations in IRF4 and NF-κB pathway genes (CARD11, CD79B, and MYD88), losses of 17p13 and gains of chromosome 7, 11q12.3-q25, whereas DLBCL, NOS was predominantly of germinal center B-cell (GCB) subtype and carried gene mutations similar to the adult counterpart (eg, SOCS1 and KMT2D), gains of 2p16/REL, and losses of 19p13/CD70. A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma–related genes such as MYC, ID3, and DDX3X and homozygous deletions of 9p21/CDKN2A, whereas other cases were genetically closer to GCB DLBCL. Factors related to unfavorable outcome were age >18 years; activated B-cell (ABC) DLBCL profile, HGBCL, NOS, high genetic complexity, 1q21-q44 gains, 2p16/REL gains/amplifications, 19p13/CD70 homozygous deletions, and TP53 and MYC mutations. In conclusion, these findings further unravel the molecular heterogeneity of pediatric and young adult LBCL, improve the classification of this group of tumors, and provide new parameters for risk stratification.

8 March 2011 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
JBJavier Ballesteros
Javier Ballesteros
MPM. Angeles Piñan
M. Angeles Piñan
PGPurificacion Garcia‐Miguel
Purificacion Garcia‐Miguel
AGAfrica Garcia‐Orad
Africa Garcia‐Orad

23 October 2012 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
JBJ Ballesteros
J Ballesteros
AGA Garcia-Orad
A Garcia-Orad

16 May 2016 in Pharmacogenomics
Verified
Journal Article
Closed access
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
IAItziar Astigarraga
Itziar Astigarraga
ANAurora Navajas
Aurora Navajas
AEAizpea Echebarria-Barona
Aizpea Echebarria-Barona
AGAfrica Garcia-Orad
Africa Garcia-Orad
Aim: Vincristine is an important component of acute lymphoblastic leukemia (ALL) treatment protocols that can cause neurotoxicity. Patients treated with LAL/SHOP protocols often suffer from vincristine-related neurotoxicity in early phases of treatment. Recently, a genome-wide association study connected a SNP in CEP72, involved in vincristine pharmacodynamics, with neurotoxicity during later phases of therapy, which was not replicated during induction phase. These results, together with previous studies indicating that polymorphisms in pharmacokinetic genes are associated with drug toxicity, suggest that changes in the activity or levels of vincristine transporters or metabolizers could work as predictors of vincristine-related neurotoxicity in early phases of treatment in pediatric ALL. Patients & methods: We analyzed 150 SNPs in eight key genes involved in vincristine pharmacokinetics and in 13 miRNAs that regulate them. We studied their correlation with neurotoxicity during induction phase in 152 ALL ...